scholarly journals Optimal ATN biomarkers and their role in predicting cognitive progress of mild cognitive impairment

2021 ◽  
Author(s):  
Rao Song ◽  
Xiaojia Wu ◽  
Huan Liu ◽  
Dajing Guo ◽  
Lin Tang ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
High Risk ◽  
Brain Mri ◽  
Progression Rate ◽  
Amyloid A ◽  
Cognitive Stability ◽  
Conversion Rates ◽  
Significant Difference ◽  
Risk Of Progression

Abstract Background It is of great significance to investigate the optimal cerebrospinal fluid (CSF) and magnetic resonance image biomarkers of ATN system and clarify their predictive value in cognitive progression of mild cognitive impairment individuals (MCI). Methods 147 healthy control (HC), 197 patients with MCI, and 128 patients with Alzheimer’ Disease (AD) were included from the ADNI database. All MCI patients were followed up from 6 to 60 months. The amyloid (A) was assessed by CSF Aβ42 or Aβ42/Aβ40. The tau pathology (T) was assessed by CSF p-tau. The neurodegeneration (N) was assessed by radiomics of the whole brain MRI or by CSF t-tau. Biomarkers with larger area under the receiver operating characteristic curve (AUC) in the discrimination of AD and HC were considered to be the optimal biomarkers. The conversion rates of different ATN profiles in MCI subjects during follow-up were analyzed using Kaplan-Meier estimates and compared using the Log-rank test. Results The CSF Aβ 42 and the radiomics signature (AUC 0.822 and 0.998, respectively) were identified as the optimal A and N biomarkers, respectively. For MCI patients of the Alzheimer continuum, there was no significant difference in the progression rate of A + T − N− and A − T−N − profiles (p > 0.05). The A + T + N−, A + T − N + profiles had a significant higher progression rate than that of the A + T − N− patients (all p < 0.05). For MCI of the suspected non-AD pathophysiology (SNAP), patients with the A − T−N + profile (p < 0.05) showed significant higher progression rate than A − T−N − profile. There was no significant difference in the progression rate of A − T + N − and A − T−N − profiles (p > 0.05). Discussion We proposed a new radiomics method to assess N accurately and ascertained the optimal A/T/N biomarkers for the discrimination of HC and AD. For MCI patients of the Alzheimer continuum, isolated A + was indicator of cognitive stability, while the abnormality of T and N, respectively or simultaneously, indicated the high risk of progression. For MCI patients of SNAP, isolated T + indicated the cognitive stability, while the appearance of N + indicated the high risk of progression.

P2-023: MILD COGNITIVE IMPAIRMENT WITH A HIGH RISK OF PROGRESSION TO ALZHEIMER'S DISEASE DEMENTIA (MCI-HR-AD): EFFECT OF SOUVENAID® TREATMENT ON COGNITION AND 18F-FDG PET SCANS

2006 ◽  
Vol 14 (7S_Part_12) ◽  
pp. P674-P675
Author(s):  
Maria Sagrario Manzano Palomo ◽  
Belen Anaya Caravaca ◽  
Maria Angeles Balsa Breton ◽  
Sergio Muñiz Castrillo ◽  
Maria Asuncion De La Morena Vicente ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
High Risk ◽  
Fdg Pet ◽  
Risk Of Progression ◽  
18F Fdg ◽  
Pet Scans ◽  
Alzheimer’S Disease Dementia

Abstract TP457: Brain Functional Alterations in Patients With Leukoaraiosis Associated Mild Cognitive Impairment

Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Na Li ◽  
Yu Mei Zhang ◽  
Yong Jun Wang
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Resting State ◽  
Brain Mri ◽  
Cingulate Cortex ◽  
Anterior Cingulate ◽  
Control Group ◽  
Hamilton Depression Scale ◽  
Brain Areas ◽  
Significant Difference

Background and aims: Recent studies demonstrated that a signal change of functional magnetic resonance imaging (fMRI) in certain brain areas during the resting state is a significant marker in patients with mild cognitive impairment (MCI). However, the research of resting-state fMRI (rs-fMRI) on leukoaraiosis (LA) associated MCI is scarce. The aim of this study was to investigate differences of the rs-fMRI default network between patients with LA-associated MCI and normal subjects, and provide functional imaging evidence of LA-associated MCI during early stages of the disease. Method: All subjects were outpatients or thier residents of the Department of Neurology of the Beijing Tiantan Hospital. They were divided into MCI group and control group according to their cognitive function assessing by the Hamilton Depression Scale, Clinical Dementia Rating (CDR), Mini Mental State Exam and Montreal Cognitive Assessment. Demographic information was recorded. Brain MRI characteristics were assessed using the Fazekas scale. The independent components of fMRI data were analyzed by fMRI tool box. The experimental data and confounding factors were analyzed by General Liner Model. Results: A total of 31 right-handed patients with LA-associated MCI and 27 right-handed healthy control subjects were included. The active areas participating in the resting state for LA-associated MCI group were mostly consistent with those of the control group. Compared with controls, the LA-associated MCI patients exhibited significantly lower blood oxygen level-dependent (BOLD) signals in the left anterior cingulate cortex (P=0.021) and right parahippocampal gyrus (P=0.032). Whereas higher BOLD signals during the resting state in LA-associated MCI patients were observed in the left caudate nucleus (P=0.015), right frontal lobe (P=0.004), superior temporal gyrus and inferior parietal gyrus (P=0.001), No significant difference was shown in the posterior cingulate cortex and precuneus (P=0.138). Conclusion: Our findings demonstrated that the discriminating functional activation in specific brain areas could be identified in patients with LA-associated MCI, which might be used as an useful neuroimaging evidence for the early recognition of these patients.

scholarly journals Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid® Treatment on Cognition and 18F-FDG PET Scans

2019 ◽  
Vol 3 (1) ◽  
pp. 95-102 ◽  
Author(s):  
Maria Sagrario Manzano Palomo ◽  
Belen Anaya Caravaca ◽  
Maria Angeles Balsa Bretón ◽  
Sergio Muñiz Castrillo ◽  
Asuncion de la Morena Vicente ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
High Risk ◽  
Fdg Pet ◽  
Risk Of Progression ◽  
18F Fdg ◽  
Pet Scans ◽  
Alzheimer’S Disease Dementia

scholarly journals Donepezil for mild cognitive impairment in Parkinson’s disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kyoungwon Baik ◽  
Seon Myeong Kim ◽  
Jin Ho Jung ◽  
Yang Hyun Lee ◽  
Seok Jong Chung ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Treatment Group ◽  
Outcome Measures ◽  
Rating Scale ◽  
Secondary Outcome ◽  
Control Group ◽  
Significant Difference

AbstractWe investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks. The primary outcome measures were the Korean version of Mini-Mental State Exam and Montreal Cognitive Assessment scores. Secondary outcome measures were the Clinical Dementia Rating, Unified Parkinson’s Disease Rating Scale part III, Clinical Global Impression scores. Progression of dementia was assessed at 48-week. Comprehensive neuropsychological tests and electroencephalography (EEG) were performed at baseline and after 48 weeks. The spectral power ratio of the theta to beta2 band (TB2R) in the electroencephalogram was analyzed. There was no significant difference in the primary and secondary outcome measures between the two groups. However, the treatment group showed a significant decrease in TB2R at bilateral frontotemporoparietal channels compared to the control group. Although we could not demonstrate improvements in the cognitive functions, donepezil treatment had a modulatory effect on the EEG in PD-MCI patients. EEG might be a sensitive biomarker for detecting changes in PD-MCI after donepezil treatment.

scholarly journals Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Zahra Ayati ◽  
Guoyan Yang ◽  
Mohammad Hossein Ayati ◽  
Seyed Ahmad Emami ◽  
Dennis Chang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Function ◽  
Daily Living ◽  
Randomised Clinical Trials ◽  
Disease Assessment ◽  
Significant Difference

Abstract Background Saffron (stigma of Crocus sativus L.) from Iridaceae family is a well-known traditional herbal medicine that has been used for hundreds of years to treat several diseases such as depressive mood, cancer and cardiovascular disorders. Recently, anti-dementia property of saffron has been indicated. However, the effects of saffron for the management of dementia remain controversial. The aim of the present study is to explore the effectiveness and safety of saffron in treating mild cognitive impairment and dementia. Methods An electronic database search of some major English and Chinese databases was conducted until 31st May 2019 to identify relevant randomised clinical trials (RCT). The primary outcome was cognitive function and the secondary outcomes included daily living function, global clinical assessment, quality of life (QoL), psychiatric assessment and safety. Rev-Man 5.3 software was applied to perform the meta-analyses. Results A total of four RCTs were included in this review. The analysis revealed that saffron significantly improves cognitive function measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale-Sums of Boxes (CDR-SB), compared to placebo groups. In addition, there was no significant difference between saffron and conventional medicine, as measured by cognitive scales such as ADAS-cog and CDR-SB. Saffron improved daily living function, but the changes were not statistically significant. No serious adverse events were reported in the included studies. Conclusions Saffron may have the potential to improve cognitive function and activities of daily living in patients with Alzheimer’s disease and mild cognitive impairment (MCI). However, due to limited high-quality studies there is insufficient evidence to make any recommendations for clinical use. Further clinical trials on larger sample sizes are warranted to shed more light on its efficacy and safety.

scholarly journals Development of a Sex-Specific Risk Scoring System for Predicting Cognitive Normal to Mild Cognitive Impairment (SRSS-CNMCI)

2021 ◽  
Author(s):  
Wen Luo ◽  
Hao Wen ◽  
Shuqi Ge ◽  
Chunzhi Tang ◽  
Xiufeng Liu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
High Risk ◽  
Scoring System ◽  
External Validation ◽  
Scoring Systems ◽  
Cutoff Point ◽  
Risk Scoring ◽  
Risk Scoring System

Abstract Objective: We aim to develop a sex-specific risk scoring system for predicting cognitive normal (CN) to mild cognitive impairment (MCI), abbreviated SRSS-CNMCI, to provide a reliable tool for the prevention of MCI.Methods: Participants aged 61-90 years old with a baseline diagnosis of CN and an endpoint diagnosis of MCI were screened from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database with at least one follow-up. Multivariable Cox proportional hazards models were used to identify risk factors associated with conversion from CN to MCI and to build risk scoring systems for male and female groups. Receiver operating characteristic (ROC) curve analysis was applied to determine the risk probability cutoff point corresponding to the optimal prediction effect. We ran an external validation of the discrimination and calibration based on the Harvard Aging Brain Study (HABS) database.Results: A total of 471 participants, including 240 women (51%) and 231 men (49%), aged 61 to 90 years, were included in the study cohort for subsequent primary analysis. The final multivariable models and the risk scoring systems for females and males included age, APOE ε4, Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). The scoring systems for females and males revealed C statistics of 0.902 (95% CI 0.840-0.963) and 0.911 (95% CI 0.863-0.959), respectively, as measures of discrimination. The cutoff point of high and low risk was 33% in females, and more than 33% was considered high risk, while more than 9% was considered high risk for males. The external validation effect of the scoring systems was good: C statistic 0.950 for the females and C statistic 0.965 for the males. Conclusions: Our parsimonious model accurately predicts conversion from CN to MCI with four risk factors and can be used as a predictive tool for the prevention of MCI.

Sign in / Sign up

Export Citation Format

Share Document